Preoperative hematological inflammatory markers associated with grade and survival in Meningiomas
Authors:
- Camila Batista de Oliveira SilvaCSCamila Batista de Oliveira Silva
- Bruna AraújoBABruna Araújo
- Bárbara Roberta OngarattiBOBárbara Roberta Ongaratti
- Tainá Mafalda dos SantosTSTainá Mafalda dos Santos
- Carolina Garcia Soares Leães RechCRCarolina Garcia Soares Leães Rech
- Lígia Barbosa CoutinhoLCLígia Barbosa Coutinho
- Nelson Pires FerreiraNFNelson Pires Ferreira
- Miriam da Costa OliveiraMOMiriam da Costa Oliveira
- Julia Fernanda Semmelmann Pereira-LimaJPJulia Fernanda Semmelmann Pereira-Lima
Open Access
- 10 March 2022
- journal article
- research article
- Published by Springer Nature in Surgical and Experimental Pathology
- Vol. 5 (1) , 1-8
Abstract
Meningiomas represent the most frequently diagnosed intracranial tumors. Inflammatory cells present in the tumor can modulate both antitumor and protumor functions, and modify the therapeutic response. Hematological inflammatory parameters have provided prognostic information useful in the treatment and clinical evaluation of several tumors. The aim of this study was to evaluate preoperative hematological markers of patients with meningiomas and to relate them to clinical variables and recurrence-regrowth free survival. Eighty-nine patients without corticosteroid therapy were included. Blood test results and tumor characteristics were collected from medical records. Associations between clinical characteristics and the recurrence-regrowth free survival (RFS) were evaluated using Cox proportional hazard analysis and Kaplan-Meier curves. The receiver operating characteristic (ROC) curves were constructed. Of the 89 cases, 73 (82%) were grade I and 16 (18%) grade II. The mean age was 53 ± 13.9 years, with higher frequency in women. Anemia was observed in 23.6% and neutrophilia in 42% of the patients. In univariate analysis, anemia (p = 0.04), neutrophilia (p = 0.02) and neutrophil/lymphocyt ratio (NLR) (p = 0.02) were associated with an increased risk of recurrence-regrowth and shorter RFS. In multivariate analysis, anemia and NLR > 4.1 represented a higher risk of recurrence-regrowth (p = 0.003). The ROC curve analysis showed that only the lymphocyte/monocyte (L/M) > 2.5 was able to predict the tumor grade. The preoperative presence of anemia, neutrophilia, NLR > 4.1 and L/M > 2.5 were associated with a worse prognosis in meningiomas. The use of preoperative hematological inflammatory parameters as prognostic factors can be promissing for evaluation and follow-up of meningiomas.Keywords
Funding Information
- CAPES (001)
This publication has 49 references indexed in Scilit:
- Anemia in malignancies: Pathogenetic and diagnostic considerationsHematology, 2014
- Microenvironmental regulation of tumor progression and metastasisNature Medicine, 2013
- The immune contexture in human tumours: impact on clinical outcomeNature Reviews Cancer, 2012
- Immune microenvironments in solid tumors: new targets for therapyGenes & Development, 2011
- The natural history of intracranial meningiomasJournal of Neurosurgery, 2011
- Sobrevida global e outros desfechos clínicos em câncer de mama: situação atual e controvérsiasRevista da Associação Médica Brasileira, 2010
- Cancer-related inflammationNature, 2008
- Hypoxia and anemia: effects on tumor biology and treatment resistanceTransfusion Clinique et Biologique, 2005
- The European Cancer Anaemia Survey (ECAS): A large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patientsEuropean Journal of Cancer, 2004
- THE RECURRENCE OF INTRACRANIAL MENINGIOMAS AFTER SURGICAL TREATMENTJournal of Neurology, Neurosurgery & Psychiatry, 1957